Preoperative anaemia is common in the Asia-Pacific. Iron-deficiency anaemia (IDA) is a risk factor that can be addressed under patient blood management (PBM) Pillar 1, leading to reduced morbidity and mortality. We examined PBM implementation under four different 
INTRODUCTION
Anaemia is a global health problem, affecting 30% of the world's population in 2015.
(1) In 2010, there were 68.4 million years lived with disability from anaemia worldwide, and 56% of these were in Asia-Pacific countries. (2) Anaemia, which is characterised by a decrease in total red blood cell (RBC) mass, is accompanied by reduced haemoglobin (Hb) levels and altered RBC morphology. As its symptoms are nonspecific and develop gradually, it often goes unnoticed and therefore untreated. Iron deficiency (ID) is the most common cause of anaemia (> 50%), (2) manifesting in decreased production of Hb and activity of iron-dependent enzymes. (3) Iron deficiency anaemia (IDA) often presents in young children and pregnant women in developing countries due to malnutrition, multiparity, postpartum haemorrhage and infectious diseases; and in the elderly due to bleeding from gastrointestinal conditions. (4) Preoperative anaemia represents a significant healthcare problem in Asia-Pacific countries. (5) (6) (7) (8) This is compounded by the limited supply of blood products: 19 (23%) out of 82 countries with low donation rates (< 10 donations per 1,000 population) are in the AsiaPacific. (9) These are typically developing countries with growing populations and a high demand for transfusions. (10) Their blood services also face difficulties in safeguarding blood stocks from risks posed by pathogens in the blood supply. (11) On the other hand, the developed countries, and even some of the less developed countries with ageing populations, have to confront the decreasing numbers of eligible donors. In addition, older persons, who have higher risks of malignancies and chronic diseases, are more likely to require complex surgical interventions. (12) 
POORER OUTCOMES FOR PATIENTS WITH PREOPERATIVE ANAEMIA
IDA is an independent risk factor for poor outcomes among patients scheduled for surgery. In a meta-analysis of observational studies, 39.1% of 949,445 patients undergoing surgery were found to be anaemic. (13) This study and others (Table I) found preoperative anaemia to be associated with greater risks of transfusion, morbidity, mortality and increased hospital length of stay (LOS). (5, 8, (14) (15) (16) (17) (18) (19) Despite these risks and the exacerbation of anaemia by surgical blood loss, preoperative anaemia is deemed acceptable by many physicians. (20) Consequently, many patients receive allogeneic RBC transfusions, which have remained the mainstay of perioperative anaemia management in many settings. This may be undesirable, as RBC transfusion is another independent risk factor for adverse outcomes such as infections and lung injury. (21) (23) Under PBM Pillar 1, a key strategy for optimising the total RBC mass of patients undergoing surgery is to identify anaemia and treat its underlying causes preoperatively. (22) For example, the Australian PBM guidelines recommend that doctors perform early evaluation and treatment of preoperative ID/IDA and its underlying causes as part of preparation for elective surgery. (24) In most cases, preoperative IDA can be corrected with iron replacement therapy. (22) Successful PBM implementation in Western Australia was associated not only with reduced blood use (i.e. RBC units/admission declined by 26% despite a 22% rise in admissions) (25) but also significant reductions in preoperative anaemia, hospital-acquired complications, in-hospital mortality and LOS, with cost savings of > AUD 6 million per year. (26) Such observations give weight to recommendations that elective surgeries be delayed until after anaemia correction. (27) Despite these reasons and the availability of therapeutic strategies and pharmacologic interventions for reducing transfusion in the perioperative setting, PBM implementation has varied widely, even in Europe and Canada where PBM has been practised for many years. (28, 29) 
CHALLENGES AND PROPOSED SOLUTIONS
We examined PBM implementation in the Asia-Pacific countries of Australia, Malaysia,
Republic of Korea and Singapore, discussing specific challenges of implementing PBM in these countries and suggesting potential solutions (Table II) . also be informed about the benefits of treating preoperative anaemia. We proposed an algorithm for the diagnosis and treatment of preoperative anaemia (Fig. 1) .
Although formal iron studies are needed prior to iron therapy, some tests may not be readily available in resource-limited settings. We suggest that an assessment of ferritin together with clinical and patient-specific risk factors can identify most IDA cases. When IDA is detected early, oral iron supplementation is usually the first-line treatment. Some side effects from the use of oral iron include nausea, constipation and vomiting, (4) which may lead to poor compliance to treatment. A systematic review has concluded that patients administered with intravenous (IV) iron experienced fewer gastrointestinal side effects compared to oral iron treatments. (30) When time is limited, IV iron infusions can be used to rapidly and effectively replenish iron stores without compromising outcomes. (31) However, in patients who urgently require reliable and rapid iron replacement, IV iron formulations such as iron sucrose, ferric gluconate, iron isomaltoside, low-molecular-weight iron dextran (LMW-ID) or ferric carboxymaltose may be better suited, as they allow the slow release of iron with marginal or no toxicity-related adverse events. (4, (32) (33) (34) Incidence rates of adverse drug events were found to be lower with modern IV iron formulations, including LMW-ID, than with older high-molecular-weight iron dextran preparations. (35) Whereas iron sucrose and ferric gluconate infusions need to be administered across several sessions, iron isomaltoside, LMW-ID or ferric carboxymaltose, which bind iron more tightly, can replenish total iron deficit in one or two doses. (4, 32) IV iron is applicable in certain instances, including immediately before surgery, post trauma, and in cases of inability to tolerate or absorb oral iron, iron loss exceeding absorption rates, and late pregnancy. (4) When there is insufficient preoperative time (e.g. trauma and emergency surgical cases), postoperative IV iron therapy has also been shown to improve Hb recovery with fewer RBC transfusions, shorter LOS and, importantly, fewer infections. (36) Clinical evidence (Table III) suggests that the use of IV iron increases the total RBC mass of patients undergoing surgery and improves outcomes. (17, (37) (38) (39) (40) (41) Even in critically ill patients, early IV iron therapy raised discharge Hb levels despite lower transfusion triggers (< 7.5 g/dL)
without compromising safety. (42) 
National health authorities
In Australia, the National Blood Authority has published comprehensive PBM guidelines since 2012. (24) In addition, the Australian Commission on Safety and Quality in Health Care hospitals were selected and supported with federal funding. They identified and implemented changes in preoperative practice in areas that were at risk for anaemia. Monthly data for 8,758
procedures (May 2015-September 2016) showed that 98% of patients were assessed for preoperative anaemia, an increase from 90%; 71% had their anaemia managed, up from 28%; 90% were assessed for ID, from 25%; and 53% had their ID managed, from 39%. (44) In Singapore, the Blood Services Group of the Health Sciences Authority, a statutory board of the Ministry of Health, supplies blood nationwide. With an ageing population (11.8%
were aged > 65 years) and life expectancy of 82.7 years, blood demand is expected to increase even as eligible donors decrease. (45) indications generated alerts via the computerised physician order entry (CPOE) system. A preliminary one-month audit of the system showed that 21% of CPOEs generated alerts for inappropriate indications and were subsequently cancelled.
Professional medical organisations
The (Table IV) . (46) (47) (48) (49) (38) RCT; 72 patients with IDA were randomly assigned to receive either (1) IV iron or (2) usual care IV iron vs. usual care:  Transfusion: 12.5% vs. 31.3% (60% reduction in RBC transfusion)  LOS: 7.0 days vs. 9.7 days; p = 0.026  Hb: improved by 0.8 g/dL vs. 0.1 g/dL by the day of admission; p = 0.01  Hb: 1.9 g/dL vs 0.9 g/dL; p = 0.01 Australia, intensive care (42) RCT; of 140 patients enrolled, (1) 70 were assigned to IV iron and (2) Republic of Korea, obstetrics and gynaecology (46) Retrospective analysis over a 10-year time frame of severely anaemic women (Hb < 50 g/L) with benign conditions who had requested not to receive a blood transfusion and given IV iron and EPO instead. Women were analysed in two groups:
(1) a gynaecologic (gyn, n = 12) and (2) an obstetric (ob, n = 7) population. Republic of Korea, bilateral total knee replacement arthroplasty (47) RCT; 108 iron-deficient patients were randomly assigned to: (1 For postpartum haemorrhage, patients who were not actively bleeding were managed in the following ways based on their Hb levels: (a) > 9 g/L -transfusion was deemed inappropriate and discouraged; (b) 7-9 g/L -transfusion was based on the need to relieve clinical signs and symptoms of anaemia, and the availability of anaemia treatment, expected delivery date and risk factors for haemorrhage; and (b) < 7 g/L -transfusion could be used but might not be required for well-compensated patients, or other therapies were available. When indicated, a single RBC unit was given followed by clinical assessment to determine further need.
BENEFITS OF PBM PILLAR 1
Our article has described the practice of PBM in four different healthcare settings. Although these examples are certainly not exhaustive, they illustrate a range of implementation approaches that can be applied in both developed and developing countries. As we and others have noted, there is an urgent need for action. (50) The anaemia burden in the Asia-Pacific region is high, with growing numbers of elderly patients who are more likely to be anaemic. (2) Without PBM, a third to half (30%-54%) (16, 18, 47) of patients undergoing surgery could require transfusion, increasing the demand for blood and potentially leading to poorer patient outcomes. Shrinking blood donor pools puts a strain on the blood supply system and may result in cancellation or postponement of elective surgery in some countries.
On the other hand, studies in the region have shown that the application of PBM Pillar 1 has led to shorter LOS, improved Hb/ferritin levels and fewer adverse events, besides reduced transfusion rates (Table IV) . (38, 42, (46) (47) (48) (49) Implementation of PBM also has a significant positive impact on healthcare costs. A 2012 study of > 100,000 patients in the canton of Zurich, Switzerland, showed a 27% reduction in RBC transfusion in the first year of implementation with direct savings of USD 2.0 million on blood products alone. (43, 51) In Australia, the National Blood Authority estimated that a 5% reduction in RBC use would save AUD 14.6 million nationally. (51) Cost savings from the use of IV iron to treat preoperative IDA were reported at USD 730 per patient (Singapore) (52) and USD 22, 192 per quality-adjusted life-year for patients with chronic heart failure (Republic of Korea) (53) in 2014. There is also the intangible cost of RBC transfusion-associated adverse outcomes and prolonged LOS. (54) While each country may face different challenges in implementing PBM, the concept is applicable everywhere. Notwithstanding its urgency, the implementation process should proceed stepwise in a manner that is appropriate to the healthcare setting and acceptable to stakeholders. Post implementation, it is also essential to apply quality assurance measures of good benchmarking, monitoring and feedback, (54) and demonstrate improved patient outcomes and safety benefits. Although this review presents PBM Pillar 1 for perioperative settings, the same principles of implementation can be extended to the other two pillars of PBM and to the non-surgical fields of medicine.
CONCLUSION
IDA is common and it is an independent modifiable risk factor for patient outcomes. Physicians and patients need to be aware of the risks of preoperative anaemia and appreciate that early treatment of IDA preoperatively can help to improve patient safety and outcomes. The most feasible way of implementing PBM is to start with small steps and expand efforts over time.
Getting PBM Pillar 1 right by using iron replacement therapy to preoperatively optimise red cell mass in patients with IDA is a sensible first step to take when embarking on PBM implementation, regardless of the healthcare setting.
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